title: The correlation of body growth with diethylnitrosamine-induced hepatocarcinogenesis in relation to serum insulin and somatomedin-C.
abstract: Caloric restriction depresses the development of several types of tumours, yet the mechanisms involved are poorly understood. In the present experiment we investigated the development of diethylnitrosamine (DEN)-induced liver tumours in mice treated with caffeine. The latter was found to reduce body growth, possibly due to increased energy expenditure, without reducing food consumption. Newborn mice received an i.p. injection of DEN. At weaning they were either fed lab chow ad libitum, with the same diet containing 0.2% (w/w) of caffeine, or their access to food was restricted to 70% of that consumed by the ad libitum group. Diet caloric restriction starting at weaning in male Swiss mice decreased the rate of development of glucose-6-phosphatase-deficient (G6Pd) preneoplastic foci. At the age of 24 weeks, 10% of the surface of a standardized liver section of ad libitum fed mice was G6Pase negative, compared to only 1% in the restricted mice due to a reduction of the number and size of these preneoplastic foci. The number and size of G6Pd foci decreased to the same extent with the ingestion of a lab chow supplemented with 0.2% of caffeine as with the diet restriction. This finding suggests that restriction slows down hepatic tumour growth by modifying body growth rather than by limited nutrient supply. In parallel, somatomedin-C (Sm-C) and insulin secretion following glucose challenge were decreased in diet restricted mice and those treated with 0.2% caffeine. The serum Sm-C and insulin levels were respectively 480 and 4.6 ng/ml in the restricted mice, 519 and 16.6 ng/ml in the caffeine-fed mice and 664 and 25.7 ng/ml in the ad libitum fed mice. Our results suggest that the decrease of secretion of these two hormones that are known mitogens for hepatocytes in vitro may be responsible at least in part for the reduction in the growth of liver tumours.
authors.affiliation: Nestec Ltd, Nestlé Research Centre, Lausanne, Switzerland.
authors.forename: L
authors.initials: L
authors.lastname: Lagopoulos
authors.forename: G I
authors.initials: GI
authors.lastname: Sunahara
authors.forename: H
authors.initials: H
authors.lastname: Würzner
authors.forename: T
authors.initials: T
authors.lastname: Fliesen
authors.forename: R
authors.initials: R
authors.lastname: Stalder
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002110:Caffeine / Q000009:adverse effects; D004052:Diethylnitrosamine / Q000008:administration & dosage / Q000633:toxicity*; D004435:Eating; D005215:Fasting; D007274:Injections, Intraperitoneal; D007328:Insulin / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008099:Liver / Q000033:anatomy & histology; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000139:chemically induced* / Q000209:etiology; D051379:Mice; D009929:Organ Size / Q000187:drug effects
chemical_list: D007328:Insulin; D002110:Caffeine; D004052:Diethylnitrosamine; D007334:Insulin-Like Growth Factor I